Together for the
Medi­cine of tomorrow

We develop our pro­jects in stra­tegic part­ner­ships – with our own know-how and a world­wide net­work in research, medi­cine and ven­ture capital.
We are look­ing for­ward to new co-operations!

Together for the Medi­cine of tomorrow

We develop our pro­jects in stra­tegic part­ner­ships – with our own know-how and a world­wide net­work in research, medi­cine and ven­ture cap­ital. We are look­ing for­ward to new co-operations!

Co-Oper­a­tions

A world­wide net­work of cooper­a­tion part­ners from pub­lic and indus­trial research insti­tu­tions forms the back­bone of many research pro­jects of ISAR Bioscience and its sci­ent­ists. Joint research and advance­ment of pro­jects is one of our char­ac­ter­ist­ics. In our col­lab­or­a­tions, we attach great import­ance to main­tain­ing the intel­lec­tual author­ship of our part­ners and to play­ing a cent­ral role in their fur­ther devel­op­ment. In this way we want to achieve our com­mon ambi­tious goals. 

With some part­ners we work in loose co-oper­a­tions, with oth­ers we enter into firm links – depend­ing on the require­ments of the respect­ive pro­ject. Below you will find some examples of such alli­ances as well as inform­a­tion on our partners.

Aca­demic partners

tum

Tech­nical Uni­ver­sity Munich, Insti­tute of Phar­ma­co­logy and Tox­ic­o­logy (Prof. Dr. Dr. Stefan Engelhardt)

The Insti­tute of Phar­ma­co­logy and Tox­ic­o­logy is part of the Bieder­stein Cam­pus of the Tech­nical Uni­ver­sity of Munich, which is loc­ated between the Munich dis­trict of Schwabing and the Eng­lish Garden. The com­pletely ren­ov­ated build­ing offers a large team of sci­ent­ists and tech­nical staff an ideal research infra­struc­ture with mod­ern labor­at­ory space and high-qual­ity sci­entific equipment.
The Research Insti­tute for Trans­la­tional Medi­cine is ded­ic­ated to the search for new thera­peut­ics for car­di­ovas­cu­lar dis­eases, which are still the main cause of death world­wide. The aim is to identify novel tar­gets for drugs, ana­lyze their func­tion and develop innov­at­ive thera­peutic strategies.
The insti­tute also coordin­ates the Munich Heart Alli­ance. With this ini­ti­at­ive, clini­cians and sci­ent­ists want to work together to improve the devel­op­ment of novel heart ther­apies. The Munich Heart Alli­ance is a part­ner loc­a­tion of the Ger­man Centre for Car­di­ovas­cu­lar Research, DZHK.

http://www.ipt.med.tu-muenchen.de/

rechts-der-isar

Klinikum rechts der Isar, Clinic and Poly­clinic for Internal Medi­cine I: Car­di­ology (Prof. Dr. Karl-Lud­wig Laugwitz/Prof. Dr. Aless­andra Moretti)

The clinic spe­cial­izes in car­di­ology, angi­ology and pneu­mo­logy, i.e. heart, vas­cu­lar and lung dis­eases. Innov­at­ive ther­apies are used to treat cir­cu­lat­ory dis­orders of the heart muscle and ves­sels, but also heart valve defects and car­diac arrhythmia as well as all lung diseases.
For many dec­ades the clinic has been known for its suc­cess­ful basic and clin­ical sci­ence at a high level. It par­ti­cip­ates in a large num­ber of clin­ical stud­ies and thus makes an import­ant con­tri­bu­tion to the devel­op­ment of mod­ern ther­apies and their safety.
A spe­cial focus is the Chair of Regen­er­at­ive Medi­cine of Car­di­ovas­cu­lar Dis­eases (Prof. Dr. Aless­andra Mor­etti). The ambi­tious goal of this research is to develop regen­er­at­ive thera­peutic approaches such as the intro­duc­tion of stem cells or dif­fer­en­ti­ated cells derived from stem cells into the defect­ive organ or the stim­u­la­tion of endo­gen­ous regen­er­a­tion pro­cesses. Numer­ous basic sci­entific ques­tions still need to be answered before a suc­cess­ful trans­la­tion can be achieved. The research group is work­ing on this using state-of-the-art sci­entific methods.

https://med1.mri.tum.de/

We enter into stra­tegic part­ner­ships with aca­demic insti­tu­tions as well as companies

Part­ners in bio­tech­no­logy and industry

ldc

Lead Dis­cov­ery Cen­ter (LDC), Dortmund and Planegg near Munich (Dr. Bert Klebl)

The Lead Dis­cov­ery Cen­ter GmbH (LDC) was foun­ded by Max Planck Innov­a­tion and the Max Planck Soci­ety to bet­ter exploit the poten­tial of excel­lent basic research. The aim is to pro­fes­sion­ally trans­fer prom­ising research pro­jects into the devel­op­ment of new drugs.
With a team of exper­i­enced sci­ent­ists, drug dis­cov­ery experts and pro­ject man­agers in the work­ing groups Medi­cinal Chem­istry, Assay Devel­op­ment & Screen­ing, Bio­logy and Phar­ma­co­logy, the LDC offers all ser­vices in the field of drug dis­cov­ery – from tar­get (bio­lo­gical tar­get struc­ture) to lead (chem­ical lead struc­ture) – accord­ing to the highest industry stand­ards. As an inde­pend­ent, com­mer­cially ori­ented com­pany, the LDC col­lab­or­ates with research insti­tu­tions, uni­ver­sit­ies and industry. It takes up prom­ising research pro­jects at early stages of devel­op­ment and jointly devel­ops them fur­ther into act­ive phar­ma­ceut­ical ingredi­ents that already provide proof-of-concept in animal studies.

https://www.lead-discovery.de/en/

assay-works

Assay­Works

The mis­sion of Assay­Works is to accel­er­ate the research pro­grams of part­ners by devel­op­ing and per­form­ing pre­dict­ive and scal­able assays to quantify the bio­activ­ity of novel chem­ical and bio­lo­gical entit­ies. Assay­Works com­bines sci­entific rigor with its expert­ise in labor­at­ory auto­ma­tion, inform­at­ics and indus­trial pro­cesses to trans­form soph­ist­ic­ated assays into quant­it­at­ive, repro­du­cible results.

https://www.assay.works/